N-Heterocycle based Degraders (PROTACs) Manifesting Anticancer Efficacy: Recent Advances.

Banerjee, Suddhasatwa; Sharma, Sachin; Thakur, Amandeep; Sachdeva, Ritika; Sharma, Ram; Nepali, Kunal; Liou, Jing Ping

Banerjee, Suddhasatwa; Sharma, Sachin; Thakur, Amandeep; Sachdeva, Ritika; Sharma, Ram; Nepali, Kunal; Liou, Jing Ping.

Afiliação

Banerjee S; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110031, Taiwan.
Sharma S; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110031, Taiwan.
Thakur A; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110031, Taiwan.
Sachdeva R; College of Medicine, Taipei Medical University, Taipei, 110031, Taiwan.
Sharma R; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110031, Taiwan.
Nepali K; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110031, Taiwan.
Liou JP; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.

Curr Drug Targets ; 24(15): 1184-1208, 2023.

Article em En | MEDLINE | ID: mdl-37946353

Assuntos

Quimera de Direcionamento de Proteólise; Ubiquitina-Proteína Ligases; Humanos; Permeabilidade; Solubilidade; Ligantes

Palavras-chave

Anticancer agent; E3 ligase; N-heterocycles; PROTACs; cancer.; protein degradation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ubiquitina-Proteína Ligases / Quimera de Direcionamento de Proteólise Limite: Humans Idioma: En Revista: Curr Drug Targets Assunto da revista: TERAPIA POR MEDICAMENTOS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Taiwan

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google